Figure 8 from Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity
Year: 2024
Type: other
Abstract: Inhibition TDO2 reduces invasion through AhR-mediated ZEB1 expression. ZEB1 protein expression in (A) BT549 with shTDO2 and (B) with shAhR (C). BT549 cells cultured in suspension for 24 hours were treated with 10 µmol/L AT-0174 or 10 µmol/L StemRegenin for 48 hours. D, BT549 treated with 10 µmol/L KYN for 48 hours. E and F, Invasion assay for BT549 shSCR control and shTDO2-82 or shAhR-85 transfected with control pcDNA3.0 or pcDNA3.0-ZEB1 expression vector. G, Linear regression between AhR and ZEB1 mRNA expression in TCGA Breast Cancer Atlas dataset with Pearson correlation analysis. H, Average AhR and ZEB1 expression in TNBC and HER2-enriched and HR+ breast cancer cell lines (n = 51). I, Average expression of TDO2, AhR, and ZEB1 from patients with basal-like and luminal A/B breast cancers. TDO2, AhR, and ZEB1 average expression from patients stratified with ER+/−. The Gene expression-based Outcome for Breast cancer Online (GOBO) database and analyzed by one-way ANOVA or t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. J, Schematic model showing TNBC with anchorage-independent conditions or inflammatory cytokine treatment can induce TDO2 and uptake TRP through LAT1, and dual inhibition of TDO2/IDO1 using AT-0174 or AhR inhibitor (StemRegenin) reduces invasion mediated by ZEB1. HR, hormone receptor; LAT1, L-type amino acid transporter 1; Lum, luminal; TCGA, The Cancer Genome Atlas.
Language: English
Topic: Cancer Cells and Metastasis
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4403467631